Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
10,884
datasets available to search
ShareScore release 0.9.0
Dataset results
10,884 results for “metastatic;”
CXCL12-loaded-hydrogel (CLG): a new device for metastatic Circulating Tumor Cells (CTCs) capturing and characterization
<p><strong>Background</strong>: Circulating Tumor Cells (CTCs) represent a small, heterogeneous population that comprise the minority of cells able to develop metastasis. To trap and characterize CTCs with metastatic attitude, a CXCL12-loaded hyaluronic-gel (CLG) was developed. CXCR4+cells with invasive capability would infiltrate CLG.<br><strong>Methods</strong>: Human colon, renal, lung and ovarian cancer cells (HT29, A498, H460 and OVCAR8 respectively) were seeded on 150 µl Empty Gels (EG) or 300 ng/ml CXCL12 loaded gel (CLG) and allowed to infiltrate for 16 hours. Gels were then digested and fixed with 2% FA-HAse for human cancer cell enumeration or digested with HAse and cancer cells recovered. CLG-recovered cells migrated toward CXCL12 and were tested for colonies/spheres formation. Moreover, CXCR4, E-Cadherin and Vimentin expression was assessed through flow cytometry and RT-PCR. The clinical trial “TRAP4MET” recruited 48 metastatic/advanced cancer patients (8 OC, 8 LC, 8 GBM, 8 EC, 8 RCC and 8 EC). 10 cc whole blood were devoted to PBMCs extraction (7cc) and ScreenCell™ filters (3cc) CTCs evaluation. Ficoll-isolated patient’s PBMCs were seeded over CLG and allowed to infiltrate for 16 hours; gels were digested and fixed with 2% FA-HAse, cells stained and DAPI+/CD45-/pan-CK+ cells enumerated as CTCs.<br><strong>Results</strong>: Human cancer cells infiltrate CLG more efficiently than EG (CLG/EG ratio 1.25 for HT29/ 1.58 for A498/ 1.71 for H460 and 2.83 for OVCAR8). CLG- recovered HT29 cells display hybrid-mesenchymal features [low E-cadherin (40%) and high vimentin (235%) as compared to HT29], CXCR4 two-fold higher than HT29, efficiently migrate toward CXCL12 (two-fold higher than HT29) and developed higher number of colonies (171±21 for HT29-CLG vs 131±8 colonies for HT29) /larger spheres (spheroid area: 26561±6142 µm2 for HT29-CLG vs 20297±7238 for HT29). In TRAP4MET clinical trial, CLG-CTCs were isolated in 8/8 patients with OC, 6/8 with LC, 6/8 with CRC, 8/8 with EC, 8/8 with RCC cancer and 5/8 with GBM. Interestingly, in OC, LC and GBM, CLG isolated higher number of CTCs as compared to the conventional ScreenCell™ (CLG/SC ratio=1.88 for OC, 2.47 for LC and 11.89 for GBM). Bland and Altman blot analysis and Passing and Bablok regression analysis showed concordance between the methodological approaches but indicate that SC and CLG are not superimposable suggesting that the two systems select cells with different features.<br><strong>Conclusion</strong>: CLG might represent a new and easy tool to isolate invasive CTCs in multiple cancers such as OC, LC and GBM at today orphan of reliable methods to consistently detect CTCs. </p>
Mutation frequency and copy number alterations determine prognosis and metastatic tropism in 60.000 clinical cancer samples
<p>The intricate interplay between somatic mutations and copy number alterations critically influences tumour evolution and patient prognosis. Traditional genomic studies often overlook this interplay by analysing these two biomarker types in isolation. We developed INCOMMON, a computational method to detect allele-specific copy number alterations from clinical targeted panels without matched normal, discover recurrent tumour-specific patterns of co-existing mutations and copy-number alterations, and stratify patients based on these composite genotypes for downstream analyses of survival, metastatic propensity and organotropism. The tool can be used as an open-source R package available at <a href="https://github.com/caravagnalab/INCOMMON">https://github.com/caravagnalab/INCOMMON</a>, and a shiny application available at <a href="https://ncalonaci.shinyapps.io/incommon/" target="_blank" rel="noopener">https://ncalonaci.shinyapps.io/incommon/</a>. This repository contains all the scripts that we used to analyse PCAWG, TCGA, MSK-MetTropism and AACR GENIE-Dfci data, and all the relevant results in the form of data tables.<strong></strong></p>
Dataset related to article "ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity"
<p>This record contains raw data related to article "ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity"</p> <p>Atypical chemokine receptors (ACKRs) are regulators of leukocyte traffic, inflammation, and immunity. ACKR2 is a scavenger for most inflammatory CC chemokines and is a negative regulator of inflammation. Here we report that ACKR2 is expressed in hematopoietic precursors and downregulated during myeloid differentiation. Genetic inactivation of ACKR2 results in increased levels of inflammatory chemokine receptors and release from the bone marrow of neutrophils with increased anti-metastatic activity. In a model of NeuT-driven primary mammary carcinogenesis ACKR2 deficiency is associated with increased primary tumor growth and protection against metastasis. ACKR2 deficiency results in neutrophil-mediated protection against metastasis in mice orthotopically transplanted with 4T1 mammary carcinoma and intravenously injected with B16F10 melanoma cell lines. Thus, ACKR2 is a key regulator (checkpoint) of mouse myeloid differentiation and function and its targeting unleashes the anti-metastatic activity of neutrophils in mice.</p>
TNM classification-based framework for the identification of metastatic progression biomarkers in pancreatic cancer dataset
<p>This data was curated from TCGA and used in the research article titled "TNM classification-based framework for the identification of metastatic progression biomarkers in pancreatic cancer". Gene sets used from MSigDB were also included.</p>
Prognostic value of a modified pathological staging system for gastric cancer based on the number of retrieved lymph nodes and metastatic lymph node ratio raw data
<p><span>Clinical data from the US Surveillance, Epidemiology, and End Results (SEER) Program from 2010-2015 (https://seer.cancer.gov/) was extracted and analyzed as training set, data from 2016-2017 was adopted as internal validation set. Data from The Cancer Genome Atlas Program (TCGA) (https://portal.gdc.cancer.gov/) and prognosis data from Gastrointestinal surgery Department, Third Affiliated Hospital of Sun Yat-sen University were applied as external validation sets. </span></p> <p><span>Screening criteria for gastric cancer cases were as follow: exclusion of cases with only autopsy or death certificate, cases where initial tumor location was not stomach, patients with stage 0 and stage IV, cases without radical surgery, non-adenocarcinoma cases, death cases within one month after operation, and cases with unknown lymph node information and AJCC TNM stage.</span></p> <p><span>The study analyzed various factors such as age of diagnosis (<50 years, 50-69 years, >69 years), gender, race (white, black, other), AJCC T stage (T1-T4b), AJCC TNM stage (I-III), primary tumor location (stomach body, antrum/pylorus, cardia/fundus, greater gastric recurve, lesser gastric recurve, overlapping area, NOS), Clinical features such as tumor size (≥5cm,<5cm, unknown), tumor grade (I-IV), chemotherapy, radiotherapy, number of lymph nodes retrieved and number of metastases, and lymph node positive rate. The populations of American Indian/Alaskan and Asian/Pacific Islander were classified as "other" due to small sample sizes. Tumor grade was also analyzed, with grades I-IV representing highly differentiated, moderately differentiated, poorly differentiated, and signed-ring cell carcinoma, respectively. Overall survival (OS) is the time from cancer diagnosis to death from any cause, while disease-specific survival (DSS) is the time from cancer diagnosis to death specifically due to the disease.</span></p> <p><strong><span> </span></strong></p>
Data to reproduce analysis in the WCDT metastatic prostate tumor subtypying paper
<p>Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen signaling. Androgen deprivation therapy and second-generation AR-targeted therapy selectively favor the development of treatment-resistant subtypes of metastatic castration resistant prostate cancer (mCRPC), defined by whether the tumor expresses either AR or neuroendocrine markers. Among the subtypes of mCRPC, the molecular drivers of double-negative (AR-/NE-) mCRPC are poorly defined. In this study, we comprehensively characterize genomic and epigenomic features of treatment-emergent mCRPC subtypes in 210 tumors by integrating matched RNA sequencing, whole-genome sequencing, and whole-genome bisulfite sequencing. We show that AR-/NE- tumors exhibit a clinically and molecularly distinct phenotype. Patients with AR-/NE- mCRPC tumors have the shortest survival, and these tumors preferentially harbor amplification of the chromatin remodeler <em>CHD7</em> and loss of <em>PTEN</em>. We demonstrate that methylation changes in <em>CHD7</em> candidate enhancers are linked to elevated <em>CHD7</em> expression in AR-/NE+ tumors. Moreover, we use genome-wide methylation analysis to nominate the Krüppel-like factor gene <em>KLF5</em> as a driver of the AR-/NE- phenotype and link its activity to loss of the tumor supressor <em>RB1</em>. These observations reveal the aggressiveness of the AR-/NE- tumors and elucidate genomic and epigenomic drivers of mCRPC subtypes, which may facilitate the identification of novel therapeutic targets in this highly aggressive disease.</p>
Search strategies for generic justification of 18F-PSMA PET/CT in the staging of primary prostate cancer and the restaging of recurrent and metastatic prostate cancer
<p>The dataset includes the complete, reproducible search strategies for all literature databases searched during this project. The search strategies address the following research questions:</p> <p>RQ 1: In the primary staging of patients with high risk prostate cancer, what is the sensitivity, specificity and diagnostic accuracy of 18F-PSMA?</p> <p>RQ 2: In patients with biochemically recurrrent prostate cancer, what is the sensitivity, specificity and diagnostic accuracy of 18F-PSMA?</p> <p>RQ 3: What is the risk of adverse events (including dose) associated with receiving 18F-PSMA?</p> <p>RQ 4: Is 18F-PSMA uptake associated with response to treatments for metastatic prostate cancer?</p>
Search strategies for 177 lu-PSMA in the treatment of metastatic castrate-resistant prostate cancer
<p>The dataset includes the complete, reproducible search strategies for all literature databases searched during this project. The search strategies were designed to answer the following research questions:</p> <p><strong>RQ1.</strong> Does the use of radioligand therapy using <sup>177</sup>Lu-PSMA lead to improved overall survival and progression-free survival, compared with other available treatment(s) in patients with metastatic, castrate-resistant prostate cancer?</p> <p><strong>RQ2.</strong> Does the use of radioligand therapy using <sup>177</sup>Lu-PSMA lead to improved quality of life or symptom control, compared with other available treatment(s), in patients with metastatic, castrate-resistant prostate cancer?</p> <p><strong>RQ3. </strong> What is the risk of adverse events and toxicity associated with radioligand therapy using <sup>177</sup>Lu-PSMA, compared with other available treatment in patients with metastatic, castrate-resistant prostate cancer?</p>
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
ClinicalTrials.gov study NCT03943667. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
ClinicalTrials.gov study NCT00290693. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
ClinicalTrials.gov study NCT00068393. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT00265850. IPD Sharing: Not stated. Countries: 2. Publications: 8.
Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer
ClinicalTrials.gov study NCT00693719. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
ClinicalTrials.gov study NCT02360579. IPD Sharing: NO. Countries: 8. Publications: 4.
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
ClinicalTrials.gov study NCT01223027. IPD Sharing: Not stated. Countries: 27. Publications: 1.
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
ClinicalTrials.gov study NCT02215161. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
ClinicalTrials.gov study NCT01661270. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
ClinicalTrials.gov study NCT01585805. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-
ClinicalTrials.gov study NCT04639245. IPD Sharing: NO. Countries: 1. Publications: 1.
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
ClinicalTrials.gov study NCT00519285. IPD Sharing: Not stated. Countries: 31. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.